Please login to the form below

Not currently logged in
Email:
Password:

idelalisib

This page shows the latest idelalisib news and features for those working in and with pharma, biotech and healthcare.

AbbVie and Roche hoping for speedy venetoclax approval

AbbVie and Roche hoping for speedy venetoclax approval

If approved, venetoclax will compete in the market with other new therapies for CLL, including Johnson &Johnson's first-in-class BTK inhibitor Imbruvica (ibrutinib) and Gilead Sciences' Zydelig (idelalisib), which

Latest news

  • NICE gives nod to Gilead’s Zydelig NICE gives nod to Gilead’s Zydelig

    Zydelig (idelalisib) has been indicated in final draft guidance for patients whose leukaemia has come back less than 24 months after previous treatment. ... had agreed to provide idelalisib to the NHS at a reduced price in the initial submission. “

  • Imbruvica filed as first-line leukaemia therapy Imbruvica filed as first-line leukaemia therapy

    Imbruvica is one of a number of new therapies for CLL reaching or near the market, with others including Gilead Sciences' Zydelig (idelalisib) and AbbVie/Roche's soon-to-be-filed

  • Roche and AbbVie's leukaemia drug set for filing by year-end Roche and AbbVie's leukaemia drug set for filing by year-end

    If approved, venetoclax will compete in the market with other new therapies for CLL, including Johnson &Johnson's first-in-class BTK inhibitor Imbruvica (ibrutinib) and Gilead Sciences' Zydelig (idelalisib), which

  • NICE opens consultation on Gilead’s leukaemia drug NICE opens consultation on Gilead’s leukaemia drug

    Specifically, England's drug pricing watchdog has opened a consultation on its preliminary draft guidance for the drug Zydelig (idelalisib) for patients with chronic lymphocytic leukaemia (CLL).

  • R&D productivity takes off R&D productivity takes off

    nitro-dihydro-imidazooxazole drug for multidrug-resistant tuberculosis (MDR-TB); Gilead Sciences' Zydelig (idelalisib) for certain types of leukaemia and lymphoma, which inhibits a protein that plays a role in the

More from news
Approximately 2 fully matching, plus 18 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. We are an award-winning agency with over 30...

Latest intelligence

Free Thinking: From promise to practice: immuno-oncology in action
...
Video: Syndicated patient record data
Track the global market in real time...
Video: Patient level prescribing decisions
...

Infographics